Methods of treating mild brain injury

Abstract

The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject, comprising administering to the subject an effective amount of a compound comprising ghrelin.

What is claimed is: 
     
       1. A method for treating mild traumatic brain injury in a subject, comprising administering to the subject between about 1.0 μg per kg bodyweight (μg/kg) to about 0.1 mg/kg of ghrelin per day. 
     
     
       2. The method of  claim 1 , wherein a selective androgen receptor modulator is not administered. 
     
     
       3. The method of  claim 1 , wherein the ghrelin has the sequence of Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (SEQ ID NO. 1). 
     
     
       4. The method of  claim 3 , wherein the ghrelin is modified with one or more fatty acids. 
     
     
       5. The method of  claim 4 , wherein the fatty acid is an octanoic acid. 
     
     
       6. The method of  claim 3 , wherein the ghrelin is modified at serine at amino acid position 2 and/or serine at amino acid position 3 of SEQ ID NO. 1. 
     
     
       7. The method of  claim 6 , wherein the ghrelin is modified at serine at amino acid position 2 and/or serine amino acid position 3 with an octanoic acid. 
     
     
       8. The method of  claim 7 , wherein modification of ghrelin is acylation of ghrelin at serine at amino acid position 2 and/or serine at amino acid position 3 with an octanoic acid. 
     
     
       9. The method of  claim 1 , wherein the subject is a mammal. 
     
     
       10. The method of  claim 1 , wherein ghrelin or a variant thereof is administered as a pharmaceutical composition. 
     
     
       11. The method of  claim 1 , wherein ghrelin is administered in a single dose. 
     
     
       12. The method of  claim 1 , wherein multiple doses of ghrelin are administered. 
     
     
       13. The method of  claim 1 , wherein the ghrelin is administered by subcutaneous injection. 
     
     
       14. The method of  claim 1 , wherein one or more symptoms of mTBI are treated. 
     
     
       15. The method of  claim 14 , wherein the one or more symptoms of mTBI comprise headache, neck pain, nausea, vomiting, dizziness, blurred vision, balance problems, sensitivity to light, sensitivity to noise, feeling slowed down, feeling “in a fog,” feeling of pressure in the head, difficulty concentrating, difficulty remembering, fatigue or low energy, confusion, drowsiness, trouble falling asleep, emotionality, irritability, sadness, nervousness, anxiety, and/or chronic traumatic encephalopathy. 
     
     
       16. The method of  claim 14 , wherein the one or more symptoms are chronic symptoms of mTBI.